Feed MLYS
ML
Mineralys Therapeutics, Inc. MLYS · NASDAQ
$15.33 +0.59% (+$0.09)
Depth
- Market cap
- $1.36B
- Enterprise value
- $1.28B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -64.7%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.69
- Free float
- 68.8%
Sector
Healthcare
Industry
Biotechnology
CEO
Jon Congleton
Employees
76
Headquarters
Radnor
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $101.3M against $25.0M.
- What to watch: It passes only 1 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
- What speaks for it: The price moves less than the market (beta 0.69).
Statements
Every number